School of Computer, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.
Evid Based Complement Alternat Med. 2013;2013:759476. doi: 10.1155/2013/759476. Epub 2013 Feb 3.
Xiaoqinglong granules (XQLG) has been shown to be an effective therapy in asthma animal models. We reviewed the literature and conducted this study to assess the impact of XQLG as an add-on therapy to treatment with fluticasone/salmeterol (seretide) in adult patients with mild-to-moderate, persistent asthma. A total of 178 patients were randomly assigned to receive XQLG and seretide or seretide plus placebo for 90 days. Asthma control was assessed by asthma control test (ACT), symptoms scores, FEV(1), and PEF. Baseline patient-reported Chinese medicine (CM)-specific symptoms were analyzed to determine whether the symptoms may be possible indicators of treatment response by conducting latent class analysis (LCA). There was no statistically significant difference in ACT score between two groups. In the subset of 70 patients with symptoms defined by CM criteria, XQLG add-on therapy was found to significantly increase the levels of asthma control according to global initiative for asthma (GINA) guidelines (P = 0.0329). There was no significant difference in another subset of 100 patients with relatively low levels of the above-mentioned symptoms (P = 0.1291). Results of LCA suggest that patients with the six typical symptoms defined in CM may benefit from XQLG.
小青龙颗粒（XQLG）已被证明是治疗哮喘动物模型的有效疗法。我们回顾了文献并进行了这项研究，以评估 XQLG 作为附加疗法对轻度至中度持续性哮喘成年患者使用氟替卡松/沙美特罗（舒利迭）治疗的影响。共有 178 名患者被随机分配接受 XQLG 和舒利迭或舒利迭加安慰剂治疗 90 天。哮喘控制通过哮喘控制测试（ACT）、症状评分、FEV1 和 PEF 评估。对基线患者报告的中药（CM）特定症状进行分析，通过潜在类别分析（LCA）确定症状是否可能成为治疗反应的指标。两组之间 ACT 评分无统计学差异。在符合 CM 标准的 70 名有症状患者亚组中，发现 XQLG 附加治疗可显著提高根据全球哮喘倡议（GINA）指南定义的哮喘控制水平（P=0.0329）。在上述症状水平相对较低的 100 名患者的另一亚组中，差异无统计学意义（P=0.1291）。LCA 的结果表明，符合 CM 中定义的六种典型症状的患者可能受益于 XQLG。
